Why sequencing beats spotting.
PCR and microarray tests work by checking a sample against a list of known mutations — they can only find what they already know to look for. Next-generation sequencing instead reads the DNA itself, base by base, across a targeted region, an exome, or an entire genome. That distinction matters clinically: a panel built to spot five known mutations will report "clear" on a sample carrying a sixth, undocumented one. NGS reads through it either way.
In practice, this means higher accuracy on the variants a panel already knows about, plus the ability to catch structural changes, novel mutations, and rare variant combinations that a fixed-marker test is architecturally unable to detect.
Precision-medicine bridgeHuman-grade standards, applied to animals.
Our team's background is in human precision medicine, where NGS-based diagnostics are now standard of care in oncology. Veterinary diagnostics has largely stayed on PCR and microarray platforms designed a decade earlier. We're bringing the same coverage depth, quality-control standards, and report design used in human clinical genomics to companion-animal testing — built for what a treating veterinarian actually needs to act on.
Peer-reviewed focusThe oncogenome of the domestic cat.
Our 2026 research contribution, The Oncogenome of the Domestic Cat, characterizes recurrent oncogenic variants across feline tumor types — the foundation for our targeted oncogene panel and a resource we continue to expand as we sequence more cases.
Validation data and study methodology are available on request for veterinary partners, investors, and grant reviewers.